Showing 5901-5910 of 6035 results for "".
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience
- Thomas Burns, CEO of Glaukos, Joins Avedro’s Board of Directorshttps://modernod.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/Avedro announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a mem
- Aussie Researchers Identify New Genetic Markers for Glaucomahttps://modernod.com/news/aussie-researchers-identify-new-genetic-markers-for-glaucoma/2479975/Australian researchers said they have identified 40 new genetic markers that increase a person’s risk of developing glaucoma, pointing to improvements in testing and predicting the risks of getting the eye disease, according to a
- Data from BioTime’s OpRegen Program to Be Presented at AAO 2018https://modernod.com/news/data-from-biotimes-opregen-program-to-be-presented-at-aao-2018/2479983/BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30
- Surgeons from Vance Thompson Vision Make Impact with Mission Trip to Hondurashttps://modernod.com/news/surgeons-from-vance-thompson-vision-make-impact-with-mission-trip-to-honduras/2479985/This spring, Russell Swan, MD, led a team of surgeons from Vance Thompson Vision and the University of Iowa, plus staff members, on a mission trip to Honduras. Russell Swan, MD, John Berdahl, MD, Brandon Baartman, MD, and Dan Bettis, MD, were joined by five team members for a week-long sur
- Genentech Unveils New Clinical Data For the First Eye Implant for Wet AMDhttps://modernod.com/news/genentech-unveils-positive-phase-2-results-for-the-first-eye-implant-for-wet-amd/2479987/Genentech announced positive topline results from the phase 2 LADDER study evaluating the efficacy and safety of its investigational Port Delivery System (PDS) with ranibizumab in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly l
- Rayner’s New UK-Based Manufacturing Facility Receives FDA Approvalhttps://modernod.com/news/rayners-new-uk-based-manufacturing-facility-receives-fda-approval/2479988/The FDA has approved Rayner’s Ridley Innovation Centre, a $40 million purpose-built R&D, training and production facility in Worthing, UK, according to a company news release. This state-of-the-art, dedicated IOL production center has the capability of manufacturing 3 million IOLs each
- Aura Biosciences Presents Interim Phase 1b/2 Data at ASRShttps://modernod.com/news/aura-biosciences-presents-interim-phase-1b-2-data-at-asrs/2479994/Aura Biosciences presented interim data from an open-label phase 1b/2 study of its lead program, light-activated AU-011 for the treatment of primary choroidal melanoma, at the 36th annual American Society of Retina Specialists (ASRS) meeting in Vancouver, Canada. The findings were presented by Am
- EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gelhttps://modernod.com/news/eyegate-announces-fda-approval-of-two-ide-submissions-for-ocular-bandage-gel/2479995/EyeGate Pharmaceuticals announced the FDA has approved two of EyeGate’s investigational device exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for the acceleration of reepithelialization of large corneal epithelial defects in patients having underg
- Thomas A. Finley, MD, Appointed Chairmen of Ocutrx International Medical Advisory Boardhttps://modernod.com/news/thomas-a-finley-md-appointed-chairmen-of-ocutrx-international-medical-advisory-board/2479996/Ocutrx Vision Technologies, a California-based augmented reality (AR) glasses developer announced that Thomas A. Finley, MD, will serve as the Chairman of the Ocutrx International Medical Advisory Board (IMAB). The board serves to advise Ocutrx in its development of augmented reality glasses for